About: Monoclonal antibodies: magic bullets with a hefty price tag

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : Monoclonal antibodies: magic bullets with a hefty price tag Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Article
Is Part Of	http://hub.abes.fr/bmj/periodical/bmj/2012/volume_345/issue_2012/w
Subject	Feature UK US
Title	Monoclonal antibodies: magic bullets with a hefty price tag
has manifestation of work	http://hub.abes.fr/bmj/periodical/bmj/2012/volume_345/issue_2012/B36F2EC43C00586AE053120B220A42AF/m/web http://hub.abes.fr/bmj/periodical/bmj/2012/volume_345/issue_2012/B36F2EC43C00586AE053120B220A42AF/m/print
related by	http://hub.abes.fr/bmj/periodical/bmj/2012/volume_345/issue_2012/B36F2EC43C00586AE053120B220A42AF/authorship/1
Abstract	Sales of monoclonal antibodies are projected to reach more than $160bn in the US alone over the next few years so is it any wonder that drug companies fiercely protect their profits? Allen Shaughnessy considers why these unique and complex drugs are so eyewateringly expensive
article type	other
publisher identifier	shau1512
is part of this journal	British Medical Journal

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata